Skip to main content

Table 2 Initial medication categories

From: Post hoc analysis of initial treatments and control status in the INITIAL study: an observational study of newly diagnosed patients with asthma

Category, n (%)

N = 4491

ICS/LABA

1054 (23.5)

LTRA

96 (2.1)

THO

4 (0.1)

SABA

15 (0.3)

LAMA/SAMA

4 (0.1)

ICS

8 (0.2)

Other single drug

10 (0.2)

ICS/LABA + other combined drugsa

2997 (66.7)

 ICS/LABA + LTRA + THO + SABA + others

49 (1.1)

 ICS/LABA + LTRA + THO + others

374 (8.3)

 ICS/LABA + LTRA + SABA + others

200 (4.5)

 ICS/LABA + LTRA + others

1833 (40.8)

 ICS/LABA + THO + others

159 (3.5)

 ICS/LABA + THO + SABA + others

11 (0.2)

 ICS/LABA + SABA + others

100 (2.2)

 ICS/LABA + others

271 (6.0)

LTRA + other combined drugsb

236 (5.3)

THO + other combined drugsc

16 (0.)

Other combined drugs

30 (0.7)

  1. ICS inhaled corticosteroid, LABA long-acting β2 agonist, LAMA long-acting muscarinic antagonist, LTRA leukotriene receptor antagonist, SABA short-acting β2 agonist, SAMA short-acting muscarinic antagonist, THO theophylline
  2. aIncluding ICS combined with LABA; bExcluding ICS/LABA, ICS or LABA; cExcluding ICS/LABA, ICS, LABA or LTRA